Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

This study compares two standard radiotherapy approaches (short-course vs. long-course) given before surgery in patients with locally advanced rectal cancer. The goal is to see which treatment is more effective and better tolerated.

Participants needed: 150
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Rajiv Gandhi Cancer Institute & Research Center, IndiaUpdated: Dec 2, 2025Locations: 1
Eligibility criteria

Histologically confirmed adenocarcinoma of the rectum [+12]

Metastatic disease at presentation (distant nodes, liver, lung, peritoneum, etc.... [+7]

Status: Recruiting

Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)

to study role of chemotherapy treatment for gall bladder cancer before surgery as compared to surgery directly

Participants needed: 114
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Rajiv Gandhi Cancer Institute & Research Center, IndiaUpdated: Apr 16, 2025Locations: 3
Eligibility criteria

ECOG 0-2 [+2]

Early GBC ( cT1/T2) without significant lymphadenopathy or liver infiltration on... [+9]

Status: Recruiting

Dose Escalation Using Hypoxia-adjusted Radiotherapy

DE-HyART is a phase II clinical trial aimed at understanding the effects of escalating radiation doses to hypoxic sub-volumes inherent to squamous cell head and neck cancer. The study is aimed at assessing locoregional control, feasibility, and acceptable toxicity with such a strategy.

Participants needed: 124
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Rajiv Gandhi Cancer Institute & Research Center, IndiaUpdated: Jan 17, 2025Locations: 1
Eligibility criteria

Age: 18 - 70 years [+11]

HPV (p16) positive tumours [+5]